Endocrine Abstracts

Background and Aims: The aim of this study was to evaluate the effects of pioglitazone (PGZ) and metformin (MET) plus Hypocaloric Diet (HD) in young patients with obesity and impaired oral glucose-tolerance test (75 g glucose).

Materials and methods: 49 patients (17.1±1.2 yrs) were allocated in groups: A (n=14) received PGZ 30 mg tid plus HD, B (n=12) - MET 1000 mg tid plus HD, C - PGZ 30 mg plus MET 1000 mg plus HD (n=11), D (n=12) were only on HD. The duration of the study was 3 months. We investigated Body Mass Index (BMI), triglyceridaemia (TG), Systolic (SBP), Diastolic Blood Pressure (DBP), insulin resistance (IR) parameters: Homeostasis Model Assesment (HOMA) - IR index; HOMA - β-cell function (HOMA-β-CF). Statitics: ANOVA.

Results: The increase of BMI, W/H, pre- and postprandial TG, HOMA-IR index (P<0.05), SBP and DPB (P<0.05) parameters, the decrease of HOMA-β-CF (P<0.05) were observed. PZG lead to the decrease of postprandial TG, HOMA-IR (P<0.05), some increase of BMI, improvement of HOMA-βCF and did not significantly influence SBP, DBP. MET was accompanied by the decrease of BMI (P<0.05), postprandial TG (P<0.05), SDP, DBP (P<0.05), but in a smaller degree, than PZG. The combined administration of PZG and MET lead to more expressed positive dynamics of investigated parameters. In particular, BMI made 26.4±3.6 (P<0.05), HOMA IR index, HOMA-βCF 0.28±0.004 (P<0.01), postprandial TG 1.77±0.03 (P<0.01), SBP (P<0.05), DBP 85.4±2.5 (P<0.05). The use of HD only lead only to some decrease of BMI (P<0.05).

Conclusion: The administration of PZG and MET in young patients with obesity and impaired OGTT is accompanied with more expressed positive dynamics of IR parameters, that allows to recommend their use in such patients.